£114.71

Springer - Resistance to Proteasome Inhibitors in Cancer

Name: Springer - Resistance to Proteasome Inhibitors in Cancer
Brand: Springer
Price: 114.71 GBP
Availability: InStock

Oncology

It has never been this cheap. We have no record of a lower price.

£115 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 39 days • 39 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 39 days • 1 price levels

Days at Price

Price Analysis

Most common price: £115 (39 days, 100.0%)

Price range: £115 - £115

Price levels: 1 different prices over 39 days

Description

This academic text from Springer examines the complex landscape of proteasome inhibitor resistance in human cancers. It provides a detailed look at why drugs like bortezomib and carfilzomib encounter challenges in treating conditions such as multiple myeloma. By investigating the molecular mechanisms behind these resistances, the book offers a deep understanding of how cancer cells adapt to targeted therapies. Readers will learn about cutting-edge strategies designed to overcome these barriers. The content covers the development of second generation 20S proteasome inhibitors and the potential of novel combinational therapies. It also explores new targets within the ubiquitin-proteasome pathway, including ubiquitin E3 ligases, deubiquitinases, and 19S proteasomal ATPases. Additional topics include the roles of histone deacetylases, oxidative stress, and proteotoxic stress pathways. The book also addresses pharmacogenomic signature profiling as a method for understanding resistant cancer cells. This resource is a valuable addition for medical professionals and researchers focused on advancing targeted anti-cancer therapeutics.

Key Features

Examines the mechanisms of action and resistance for proteasome inhibitors like bortezomib and carfilzomib in human cancers.

Explores second generation 20S proteasome inhibitors and novel combinational therapy strategies to combat drug resistance.

Identifies new targets in the ubiquitin-proteasome pathway, such as ubiquitin E3 ligases and deubiquitinases.

Covers the impact of 19S proteasomal ATPases, histone deacetylases, and oxidative stress on resistant cancer cells.

Discusses pharmacogenomic signature profiling and proteotoxic stress pathways in the context of targeted therapeutics.

Product Specifications

Brand: Springer
Format: paperback
ASIN: 3319377035
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 22 September 2016
Listed Since: 08 July 2016

Barcode

No barcode data available

Springer - Resistance to Proteasome Inhibitors in Cancer

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Key Features

Product Specifications

Barcode

Similar Products You Might Like

Precision Cancer Therapies, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice: 1 (Precision Cancer Therapies, Volume 1)

Small Molecules in Oncology: 211 (Recent Results in Cancer Research, 211)

Small Molecules in Oncology: 211 (Recent Results in Cancer Research, 211)

Small Molecules for Cancer Treatment

Cellular and Molecular Biology of Metals

Apoptosis and Cancer Chemotherapy (Cancer Drug Discovery and Development)

Personalized Cancer Chemotherapy: An Effective Way of Enhancing Outcomes in Clinics

Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications (Pharmaceutical Science Series)

Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)

Side Effects of Medical Cancer Therapy: Prevention and Treatment

Small Molecules in Hematology: 212 (Recent Results in Cancer Research, 212)

Springer - The Cancer Degradome: Proteases and Cancer Biology

Mutant p53 and MDM2 in Cancer: 85 (Subcellular Biochemistry, 85)

Springer Mutant p53 and MDM2 in Cancer - Subcellular Biochemistry 85

Humana Cancer Cell Signaling: Methods and Protocols 218

Humana Combination Cancer Therapy: Modulators and Potentiators

Metastasis Research Protocols: 1070 (Methods in Molecular Biology, 1070)

Springer Biochemical Modulation of Anticancer Agents Book

Towards Dual and Targeted Cancer Therapy with Novel Phthalocyanine-based Photosensitizers (Springer Theses)

Immune Mediators in Cancer: Methods and Protocols: 2108 (Methods in Molecular Biology, 2108)

Tumor Suppressor Genes in Human Cancer (Cancer Drug Discovery and Development)

Improving the Therapeutic Ratio in Head and Neck Cancer (Volume 6) (Cancer Sensitizing Agents for Chemotherapy, Volume 6)

Cell Surface GRP78, a New Paradigm in Signal Transduction Biology

Tumor Suppressor Genes in Human Cancer (Cancer Drug Discovery and Development)